CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
PHNO +5 moredrug
Likely dose
Placebo oral capsule 0.5 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03103750
NCT03103750Phase 1Completed

Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Study of Stimulant-induced Dopamine Release Using [11C]-PHNO PET in Healthy Humans

Yale University·interventional·Posted Apr 6, 2017·Updated Mar 19, 2024

In Brief

A Phase 1 clinical trial evaluating Magnetic Resonance Imaging (MRI), PHNO, and 4 other interventions for ADHD. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Specific Aim 1: As part of a within-subject, two-days, study design, to determine whether acute calcitriol (vs. placebo) pre-treatment is associated with greater amphetamine (Amp)-induced dopamine (DA) release in the caudate, putamen, ventral striatum (VST), and substantia nigra / ventral tegmental area (SN/VTA) of healthy human subjects. Specific Aim 2: To determine whether acute calcitriol (vs. placebo) pre-treatment is associated with better performance on a test of attention (e.g., the Continuous Performance Task or CPT-IP), after treatment with amphetamine. Hypothesis: Investigators hypothesize that Subjects pre-treated with calcitriol will have faster reaction times/higher accuracy on the CPT-IP vs. subjects pre-treated with placebo, after treatment with amphetamine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsADHD
CountriesUnited States

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedApr 6, 2017
Enrollment StartAug 15, 2017
Primary CompletionJan 17, 2023
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 9.2 years ago

Interventions

Magnetic Resonance Imaging (MRI)procedure

Magnetic resonance imaging (MRI) scans (3 T) will be collected in each subject for the purposes of excluding participants with anatomical abnormalities and anatomically co-registering PET and MRI for image analysis

PHNOdrug

Used as a tracer for in vivo imaging.

calcitrioldietary

three 0.5 mcg capsules

Placebo oral capsuledrug

three 0.5 mcg capsules

high-resolution research tomographyprocedure

A functional imaging technique that is used to observe metabolic processes in the body.

Dextro Amphetaminedrug

Dexedrine 0.3 mg/kg, to a maximum dose of 30 mg